STO · STIL.ST
Stille AB
SEK 250.00SEK 0.00 (0.0%)
Stille AB’s quoted price sits in the upper half of its reported 52-week range, 11.66% below the high.
Loading market information…
STO · GENO.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Genovis AB’s quoted price sits in the upper half of its reported 52-week range, 7.82% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Genovis AB’s next earnings report is currently expected on Nov 10, 2026, with estimated earnings per share of SEK 0.05. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Genovis AB’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues. In addition, the company offers OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; OpeRATOR, an O-glycan-specific protease; ImpaRATOR, an O-glycan-dependent protease; OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; and GlycOCATCH, an affinity resin. Further, it provides GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a family of antibody products; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as SEQURNA RNase Inhibitor Thermostable. Additionally, the company offers antibodies, proteins, antigens, kits, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services. It serves biotech and pharmaceutical, contract research, and contract manufacturing companies. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:24 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 21, 2025 | SEK 0.05-50.0% vs estimate | SEK 32.29M+7.52% vs estimate |
|---|
| Q4 2024 | Feb 14, 2025 | SEK 0.07+16.67% vs estimate | SEK 27.94M-10.46% vs estimate |
|---|
| Q3 2024 | Nov 8, 2024 | SEK 0.21+133.33% vs estimate | SEK 32.90M+15.22% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 250.00SEK 0.00 (0.0%)
Stille AB’s quoted price sits in the upper half of its reported 52-week range, 11.66% below the high.
SEK 24.15-SEK 0.10 (-0.41%)
BICO Group AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 5.0% below the high.
SEK 68.40+SEK 1.20 (+1.79%)
Paxman AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.58% below the high.
SEK 16.76-SEK 0.72 (-4.12%)
SynAct Pharma AB’s quoted price sits in the upper half of its reported 52-week range, 31.87% below the high.
SEK 58.70-SEK 0.30 (-0.51%)
I-Tech AB’s quoted price sits in the lower half of its reported 52-week range, 27.35% below the high.
SEK 1.71+SEK 0.05 (+3.07%)
Oncopeptides AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 72.13% below the high.
SEK 10.70+SEK 0.22 (+2.1%)
Xspray Pharma AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 70.4% below the high.
SEK 1.67+SEK 0.20 (+13.2%)
Cantargia AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 74.63% below the high.
